📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-26 13:50
144 analysed today
144
Today
136,664
All-time analysed
40,493
Positive
6,319
Negative
81,911
Neutral
7,873
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
3 announcements match the current filters (relevance ≥ 5).
Zenith Drugs allots 16.09 lakh warrants to promoters to raise up to ₹7.00 Cr at ₹43.50/share
Zenith Drugs Limited has approved the allotment of 16,09,050 convertible warrants to promoter group members at an issue price of ₹43.50 per warrant, aggregating up to ₹7.00 Cr. The company has received 25% upfront subscription consideration amounting to ₹1.75 Cr (₹1,74,98,421), with the balance 75% payable upon warrant conversion within 18 months. Upon full exercise, the allottees' collective holding will increase from 64.08% to 67.16%. Additionally, Executive Director Ajay Singh Dassundi has been re-designated as a Non-Executive Director effective August 27, 2026.
Confidence: HIGH
What changedThe Board allotted 16.09 lakh convertible warrants raising ₹1.75 Cr upfront from promoters and re-designated promoter Ajay Singh Dassundi to Non-Executive Director.
Why it mattersThe preferential issue demonstrates promoter commitment at ₹43.50 per share (above the prevailing market price of ₹41.20), infusing growth capital into the balance sheet.
Total fundraise value: ₹6.99 CrUpfront consideration received (25%): ₹1.75 CrIssue price per warrant: ₹43.50Fundraise vs Market Cap: ~10.0%Conversion window: 18 months
📅 Short termPositive sentiment given promoter backing and equity capital injection above the recent trading market price.
📈 Long termStrengthens the equity base and liquidity to support ongoing business expansion and high working capital requirements.
⚠ Risk flags
- Equity dilution of ~8.6% upon full conversion of warrants into equity shares
- Warrants lapse if remaining 75% consideration is not paid within 18 months
Key Highlights
Allotted 16,09,050 convertible warrants at ₹43.50 per warrant (FV ₹10 + premium ₹33.50) on preferential basis
Total issue size of ₹7.00 Cr (~10% of current market cap of ₹70 Cr)
Received ₹1.75 Cr upfront (25% consideration); balance 75% payable within 18 months
Allotted equally (5,36,350 warrants each) to 3 promoters: Ajay Singh Dassundi, Sandeep Bhardwaj, and Bhupesh Soni
Allottees' combined shareholding will rise from 64.08% to 67.16% upon full conversion
👀 What to Watch
Track the deployment of funds toward working capital or the planned ₹20 Cr capex, along with the timeline for conversion of the remaining 75% warrant balance.
Zenith Drugs Allots 16.09 Lakh Promoter Warrants at Rs 43.50 to Raise Up to Rs 7.00 Cr
Zenith Drugs' Board has approved the allotment of 16,09,050 convertible warrants to three promoters at an issue price of Rs 43.50 per warrant on a preferential basis. The company received 25% upfront subscription money of Rs 1.75 Cr out of the total Rs 7.00 Cr issue size (~10.0% of market cap). Upon full exercise within 18 months, the combined stake of the three allottees will rise from 64.08% to 67.16%. In addition, Executive Director Ajay Singh Dassundi was re-designated as a Non-Executive Director effective August 27, 2026.
Confidence: HIGH
What changedZenith Drugs allotted 16.09 lakh convertible warrants to promoters on receiving 25% upfront consideration and re-designated promoter Ajay Singh Dassundi as Non-Executive Director.
Why it mattersProvides up to Rs 7.00 Cr of promoter-backed equity capital at Rs 43.50 (above the prevailing market price of Rs 41.2), strengthening the balance sheet and supporting working capital needs.
Total Issue Size: Rs 6,99,93,675Upfront Consideration Received (25%): Rs 1,74,98,421Issue Price per Warrant: Rs 43.50Warrants Allotted: 16,09,050Fundraise vs Market Cap: ~10.0%
📅 Short termPromoter capital infusion priced at Rs 43.50 per share provides near-term pricing support against the current trading price.
📈 Long termPromoter commitment through equity warrant subscription reinforces backing for operational scale-up, though full conversion will modestly dilute non-promoter equity.
⚠ Risk flags
- Equity dilution of ~8.6% on existing share capital upon full warrant conversion
- Risk of warrant forfeiture if the remaining 75% consideration is not paid within the 18-month window
Key Highlights
Allotment of 16,09,050 convertible warrants approved at Rs 43.50 each (face value Rs 10 + premium Rs 33.50), aggregating to Rs 6,99,93,675
Received 25% upfront application money of Rs 1,74,98,421 (~Rs 1.75 Cr), with 75% balance payable upon exercise within 18 months
Allotment split equally among three promoters (Ajay Singh Dassundi, Sandeep Bhardwaj, Bhupesh Soni) at 5,36,350 warrants each
Promoter group allottees' holding to expand from 64.08% (1.09 Cr shares) to 67.16% (1.26 Cr shares) post-conversion
Ajay Singh Dassundi re-designated from Executive Director to Non-Executive (Non-Independent) Director w.e.f. August 27, 2026
👀 What to Watch
Track the deployment of the initial Rs 1.75 Cr proceeds and watch for subsequent warrant exercise notices and receipt of the balance 75% funds over the 18-month tenure.
Zenith Drugs Allots 16.09 Lakh Promoter Warrants to Raise ₹7.00 Cr; Board Approves Leadership Change
Zenith Drugs Limited's board approved the allotment of 16,09,050 convertible warrants at ₹43.50 per warrant to three promoters, raising an aggregate of ₹7.00 Cr (~10% of market cap). The company received ₹1.75 Cr (25% upfront subscription consideration), with the remaining 75% payable upon warrant exercise within 18 months. Upon full conversion, the three promoters' combined shareholding will increase from 64.08% to 67.16%. Additionally, Executive Director Ajay Singh Dassundi has been re-designated as a Non-Executive (Non-Independent) Director effective August 27, 2026.
Confidence: HIGH
What changedAllotted 16.09 lakh convertible warrants to 3 promoters at ₹43.50/share and re-designated an Executive Director to Non-Executive role.
Why it mattersProvides immediate liquidity of ₹1.75 Cr (up to ₹7.00 Cr total), demonstrating promoter confidence at an issue price above the current market price of ₹41.20.
Total warrants allotted: 16,09,050Issue price per warrant: ₹43.50Total fundraise value: ₹6,99,93,675Upfront consideration (25%): ₹1,74,98,421Fundraise vs Market Cap: ~10.0%Warrant exercise window: 18 months
📅 Short termPositive for sentiment as promoters infuse fresh equity capital at a premium to the prevailing market price.
📈 Long termStrengthens net worth and supports working capital and expansion requirements, though subject to 18-month conversion timelines.
⚠ Risk flags
- Full ₹7.00 Cr realization depends on promoters exercising the warrants within 18 months
- Dilution of non-promoter public shareholding upon conversion
Key Highlights
Allotted 16,09,050 convertible warrants at an issue price of ₹43.50 each (face value ₹10 + premium ₹33.50)
Total capital to be raised amounts to ₹6,99,93,675 (~₹7.00 Cr), with ₹1,74,98,421 (25%) received upfront
Allotted equally (5,36,350 warrants each) across 3 promoters: Ajay Singh Dassundi, Sandeep Bhardwaj, and Bhupesh Soni
Promoter group holding across the 3 allottees will expand from 64.08% to 67.16% post-full conversion
Re-designated Ajay Singh Dassundi from Executive Director to Non-Executive Director w.e.f. August 27, 2026
👀 What to Watch
Monitor the exercise timeline of warrants over the 18-month window and utilization of funds toward the company's planned ₹20 Cr capex.
